The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Atypical Hemolytic Uremic Syndrome
Open accessAbstract
Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement overactivation. Inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described. Incomplete penetrance of mutations in all predisposing genes is reported, suggesting that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The underlying genetic defect predicts the prognosis both in native kidneys and after renal transplantation. The successful trials of the complement inhibitor eculizumab in the treatment of atypical HUS will revolutionize disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Eculizumab, a recombinant humanized monoclonal antibody directed against C5, blocks the cleavage of C5 into its effector components C5a and C5b.(106) Since the initial use of this complement inhibitor in aHUS in 2009,(107) the effectiveness of eculizumab has been communicated in many case reports, meeting abstracts, a…”
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature · doi:10.1038/nature10449 · Cited by 533
Complement factor H binds to denatured rather than to native pentameric C-reactive protein
Hakobyan, S., Harris, C. L., van den Berg, C. W., Fernandez-Alonso, M. C., de Jorge, E. G., de Cordoba, S. R., Rivas, G., Mangione, P., Pepys, M. B., & Morgan, B. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803648200 · Cited by 90
Cited by
Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationComplement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Thrombotic Microangiopathy and the Kidney
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00620117 · Cited by 373
Self-citationDynamics of complement activation in aHUS and how to monitor eculizumab therapy
Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558296 · Cited by 341
Atypical aHUS: State of the art
Nester, C. M., Barbour, T., de Cordoba, S. R., Dragon-Durey, M. A., Fremeaux-Bacchi, V., Goodship, T. H. J., Kavanagh, D., Noris, M., Pickering, M., Sanchez-Corral, P., et al. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.246 · Cited by 299
Self-citation
Metadata
- Authors
- Kavanagh, D., Goodship, T. H., & Richards, A.
- Venue
- Seminars in Nephrology
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 33
- Issue
- 6
- Pages
- 508-530
- ISSN
- 0270-9295 (ISSN-L)
- OpenAlex
- W2149943632
- Cited by
- 348
- References
- 4
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atypical Hemolytic Uremic Syndrome. https://app.cochat.ai/papers/10.1016/j.semnephrol.2013.08.003
- The paper
- Kavanagh, D., Goodship, T. H., & Richards, A. (2013). Atypical Hemolytic Uremic Syndrome. Seminars in Nephrology. https://doi.org/10.1016/j.semnephrol.2013.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.